A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 3 Ascending Dose Levels of a 4-antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to < 86 Years

Trial Profile

A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 3 Ascending Dose Levels of a 4-antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to < 86 Years

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Staphylococcus aureus vaccine (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Apr 2017 Results (n=440) of this and one other study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 30 Oct 2016 Results from this and other study presented at the IDWeek 2016.
    • 11 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top